GILD
Gilead Sciences Inc
150.90$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 25.6% | 25.9% | 24.9% | 23.0% | 27.1% | 32.5% | 29.9% | 26.4% | 30.5% | 31.1% | 33.1% | 28.3% | |
| 9.1% | 9.8% | 8.4% | 5.2% | 9.2% | 16.9% | 14.0% | 9.2% | 12.5% | 12.8% | 13.6% | 6.4% | |
| 11.0% | 13.4% | 10.8% | 7.8% | 12.3% | 19.6% | 14.0% | 9.4% | 12.6% | 16.3% | 13.6% | 6.4% | |
| 7.7% | 7.5% | 8.3% | 8.7% | 8.4% | 7.5% | 7.8% | 8.6% | 8.7% | 8.3% | 8.4% | 10.2% | |
| 2.7% | 2.9% | 3.3% | 3.8% | 3.4% | 2.9% | 3.1% | 3.3% | 3.0% | 3.0% | 3.4% | 4.0% | |
| 13.3% | 13.4% | 14.8% | 15.5% | 15.2% | 14.1% | 14.7% | 14.9% | 14.2% | 14.1% | 14.8% | 16.8% | |
| 43.5% | 42.6% | 41.6% | 42.6% | 37.7% | 33.8% | 34.3% | 33.3% | 30.7% | 28.8% | 29.1% | 28.4% | |
| 64.3% | 63.4% | 69.0% | 66.0% | 66.3% | 67.4% | 66.2% | 64.8% | 63.3% | 61.7% | 58.4% | 76.2% | |
| 19.2% | 18.2% | 23.1% | 20.1% | 21.5% | 20.3% | 21.9% | 20.1% | 21.0% | 20.0% | 16.8% | 22.3% | |
| 2.9% | 3.1% | 6.5% | 3.4% | 3.3% | 3.3% | 5.0% | 5.0% | 4.8% | 4.8% | 2.3% | 4.9% | |
| 0.9% | 0.9% | 1.1% | 1.0% | 1.7% | 1.4% | 1.3% | 1.0% | 1.4% | 1.2% | 1.1% | 1.4% | |
| 37.2% | 37.3% | 38.2% | 40.2% | 39.3% | 42.2% | 39.2% | 39.7% | 37.8% | 37.5% | 37.1% | 48.3% | |
| 35.8% | 36.8% | 31.2% | 34.1% | 33.9% | 32.8% | 34.0% | 35.3% | 36.8% | 38.5% | 41.8% | 24.0% | |
| 25.7% | 26.2% | 18.9% | 20.8% | 20.3% | 19.5% | 19.4% | 20.3% | 21.9% | 23.3% | 25.1% | 4.5% | |
| 2.0% | 2.0% | 2.2% | 2.3% | 2.3% | 2.1% | 2.2% | 2.3% | 2.1% | 2.1% | 2.2% | 2.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.